A Phase 1/2 interventional study of Relatlimab and Nivolumab in Lymphoma, Non-Hodgkin and Hodgkin Disease, sponsored by Bristol-Myers Squibb. Terminated at 51 sites in 7 countries. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing nivolumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. Nivolumab · Lymphoma, Non-Hodgkin.
Among the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, this one is the 12th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1/2, and was the 12th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin are open now, in 3 countries. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 3–39
Canadian Cancer Trials Group · Sites in Canada
Ages 18+
American Society of Clinical Oncology · Sites in United States, Puerto Rico
Ages 12+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: Up to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 1
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 109 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb: 2 open now, 5 under way, none of them phase 3. Of 42 finished, 25 (60%) have results posted.
Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 43rd largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 1/2, and was the 46th registered.
Bristol-Myers Squibb’s Lymphoma, Non-Hodgkin studies by the year they started, since 2004.
1 of the studies testing nivolumab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03297606Canadian Cancer Trials GroupCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 50 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Relatlimab · Drug: Nivolumab
Specified Dose on Specified Days
Also known as: BMS-986016
Specified Dose on Specified Days
Also known as: BMS-936558
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A
Hepatic DLT * ALT or AST \> 8 × ULN * ALT or AST \> 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention. * TB \> 5 × ULN. * ALT or AST \> 3 × ULN and concurrent total bilirubin \> 2 × ULN. Non-Hematologic DLT * ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment. * ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below. Hematologic DLT * Grade 4 anemia not explained by underlying disease. * Grade 3 febrile neutropenia lasting \> 48 hours, or Grade 4 febrile neutropenia * Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor. * Grade 3 thrombocytopenia associated with clinically significant bleeding. * Grade 3 hemolysis
Time frame: 1 cycle, defined as 28 days
Complete Metabolic Response (CMR) Rate - Part B
The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria. No participants enrolled in Part B.
Time frame: From first dose until the first documented response
Number of Participants With Adverse Events (AEs) - Part A
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants Who Died - Part A
Number of participants who died due to any cause
Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Serious Adverse Events (SAEs) - Part A
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Laboratory Abnormalities - Part A
Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death
Time frame: From first dose to 30 days post last dose (Up to approximately 8 months)
Maximum Serum Concentration (Cmax)
Maximum observed serum concentration of Analyte BMS-986016
Time frame: Cycle 1 Day 1
Time to Maximum Concentration (Tmax)
Time of maximum observed serum concentration of Analyte BMS-986016
Time frame: Cycle 1 Day 1
Area Under the Concentration-time Curve [AUC(TAU)]
Area Under the Concentration-time Curve \[AUC(TAU)\] for Analyte BMS-986016
Time frame: Cycle 1 Day 1
Concentration Trough (Ctrough)
Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558
Time frame: Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1
Number of Participants With Adverse Events (AEs) - Part B
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.
Time frame: From first dose to 135 days post last dose
Number of Participants With Serious Adverse Events (SAEs) - Part B
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization. No participants enrolled in part B.
Time frame: From first dose to 135 days post last dose
Number of Participants With Adverse Events Leading to Discontinuation - Part B
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.
Time frame: From first dose to 135 days post last dose
Number of Participants Who Died - Part B
Number of participants who died due to any cause. No participants enrolled in part B.
Time frame: From first dose to 135 days post last dose
Number of Participants With Laboratory Abnormalities - Part B
No participants enrolled in part B.
Time frame: From first dose to 135 days post last dose
Objective Response Rate (ORR) - Part B
ORR is defined as the percentage of all response evaluable participants who achieve a best response of CMR or PMR using the Lugano 2014 classification. No participants enrolled in part B
Time frame: From to
| Milestone | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Started | 4 | 1 |
| Completed | 0 | 0 |
| Not completed | 4 | 1 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Maximum clinical benefit | 1 | 0 |
| Withdrew: Disease progression | 2 | 1 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.
No measurements were reported for this outcome.
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization. No participants enrolled in part B.
No measurements were reported for this outcome.
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. No participants enrolled in part B.
No measurements were reported for this outcome.
Number of participants who died due to any cause. No participants enrolled in part B.
No measurements were reported for this outcome.
No participants enrolled in part B.
No measurements were reported for this outcome.
Hepatic DLT * ALT or AST \> 8 × ULN * ALT or AST \> 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention. * TB \> 5 × ULN. * ALT or AST \> 3 × ULN and concurrent total bilirubin \> 2 × ULN. Non-Hematologic DLT * ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment. * ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below. Hematologic DLT * Grade 4 anemia not explained by underlying disease. * Grade 3 febrile neutropenia lasting \> 48 hours, or Grade 4 febrile neutropenia * Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor. * Grade 3 thrombocytopenia associated with clinically significant bleeding. * Grade 3 hemolysis
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A | 0 | 0 |
The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria. No participants enrolled in Part B.
No measurements were reported for this outcome.
ORR is defined as the percentage of all response evaluable participants who achieve a best response of CMR or PMR using the Lugano 2014 classification. No participants enrolled in part B
No measurements were reported for this outcome.
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) - Part A | 4 | 1 |
Number of participants who died due to any cause
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Number of Participants Who Died - Part A | 0 | 1 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) - Part A | 1 | 1 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A | 0 | 0 |
Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death
| Participants | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Grade ≥ 3 Hematology | 1 | 0 |
| Grade ≥ 3 Serum Chemistry | 0 | 0 |
Maximum observed serum concentration of Analyte BMS-986016
| ug/mL | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Maximum Serum Concentration (Cmax) | 51.83 ± 16 | 40.00 ± NA |
Time of maximum observed serum concentration of Analyte BMS-986016
| hour | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Time to Maximum Concentration (Tmax) | 0.74 (0.58 to 1.00) | 0.50 (0.50 to 0.50) |
Area Under the Concentration-time Curve \[AUC(TAU)\] for Analyte BMS-986016
| h*ug/mL | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Area Under the Concentration-time Curve [AUC(TAU)] | 13160.63 ± 32 | 6745.58 ± NA |
Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558
| ug/mL | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Cycle 2 Day 1 - BMS986016 | 9.50 ± 68 | 2.39 ± NA |
| Cycle 4 Day 1 - BMS986016 | 20.52 ± 66 | — |
| Cycle 6 Day 1 - BMS986016 | 23.53 ± NA | — |
| Cycle 2 Day 1 - BMS-936558 | 40.32 ± 46 | 17.80 ± NA |
| Cycle 4 Day 1 - BMS-936558 | 79.80 ± 53 | — |
| Cycle 6 Day 1 - BMS-936558 | 91.87 ± NA | — |
Collected over All-Cause Mortality (ACM) was assessed from randomization until their study completion (Up to approximately 38 months). Adverse Events (AEs) and Serious Adverse (SAEs) were assessed from first dose to 135 days post last dose (Up to approximately 11 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Flat Dosing (AF) | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part A - Age/Weight-based Dosing (AW) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Event | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| Facial painGeneral disorders and administration site conditions | 0/4 | 1/1 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 1/1 |
| Spinal cord compressionNervous system disorders | 0/4 | 1/1 |
| Skin infectionInfections and infestations | 1/4 | 0/1 |
| Event | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) |
|---|---|---|
| ToothacheGastrointestinal disorders | 0/4 | 1/1 |
| PyrexiaGeneral disorders and administration site conditions | 1/4 | 1/1 |
| Otitis mediaInfections and infestations | 0/4 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 2/4 | 0/1 |
| LymphopeniaBlood and lymphatic system disorders | 2/4 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 0/1 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/4 | 0/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/4 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 0/1 |
| HyperthyroidismEndocrine disorders | 1/4 | 0/1 |
| Age, Categorical(Participants) | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) | Total |
|---|---|---|---|
| <=18 years | 4 | 1 | 5 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 1 | 3 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Part A - Flat Dosing (AF) | Part A - Age/Weight-based Dosing (AW) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 4 | 0 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in Dec 2025, 38 months.
Results were first posted in Jun 2026, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Nivolumab